CN114269381A - 用于治疗甲型流感感染的抗体和方法 - Google Patents

用于治疗甲型流感感染的抗体和方法 Download PDF

Info

Publication number
CN114269381A
CN114269381A CN202080034142.3A CN202080034142A CN114269381A CN 114269381 A CN114269381 A CN 114269381A CN 202080034142 A CN202080034142 A CN 202080034142A CN 114269381 A CN114269381 A CN 114269381A
Authority
CN
China
Prior art keywords
antibody
seq
nucleic acid
influenza
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080034142.3A
Other languages
English (en)
Chinese (zh)
Inventor
达维德·科尔蒂
法比奥·贝尼尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Priority to CN202411518877.XA priority Critical patent/CN119192357A/zh
Publication of CN114269381A publication Critical patent/CN114269381A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080034142.3A 2019-04-30 2020-04-30 用于治疗甲型流感感染的抗体和方法 Pending CN114269381A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411518877.XA CN119192357A (zh) 2019-04-30 2020-04-30 用于治疗甲型流感感染的抗体和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/061134 WO2020221450A1 (en) 2019-04-30 2019-04-30 Antibodies and methods for treatment of influenza a infection
EPPCT/EP2019/061134 2019-04-30
PCT/EP2020/062160 WO2020221908A1 (en) 2019-04-30 2020-04-30 Antibodies and methods for treatment of influenza a infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411518877.XA Division CN119192357A (zh) 2019-04-30 2020-04-30 用于治疗甲型流感感染的抗体和方法

Publications (1)

Publication Number Publication Date
CN114269381A true CN114269381A (zh) 2022-04-01

Family

ID=66429359

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080034142.3A Pending CN114269381A (zh) 2019-04-30 2020-04-30 用于治疗甲型流感感染的抗体和方法
CN202411518877.XA Pending CN119192357A (zh) 2019-04-30 2020-04-30 用于治疗甲型流感感染的抗体和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411518877.XA Pending CN119192357A (zh) 2019-04-30 2020-04-30 用于治疗甲型流感感染的抗体和方法

Country Status (17)

Country Link
US (1) US20220226470A1 (https=)
EP (1) EP3962530A1 (https=)
JP (1) JP7719725B2 (https=)
KR (1) KR20220003000A (https=)
CN (2) CN114269381A (https=)
AU (1) AU2020265407B2 (https=)
BR (1) BR112021018409A2 (https=)
CA (1) CA3132536A1 (https=)
CL (1) CL2021002807A1 (https=)
CO (1) CO2021012583A2 (https=)
EA (1) EA202192923A1 (https=)
IL (1) IL287423A (https=)
MX (1) MX2021012984A (https=)
PH (1) PH12021552176A1 (https=)
SG (1) SG11202109683TA (https=)
TW (1) TW202106707A (https=)
WO (2) WO2020221450A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115052630A (zh) * 2019-08-29 2022-09-13 维尔生物科技有限公司 用于治疗甲型流感感染的组合物和方法
CN115777944A (zh) * 2023-02-10 2023-03-14 北京衡美金叶营养健康科技有限公司 增强身体防御力的组合物及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
US20230340083A1 (en) * 2020-12-08 2023-10-26 Vir Biotechnology, Inc. Antibodies and methods for treatment of influenza a infection
CN112812095A (zh) * 2021-01-29 2021-05-18 成都安满生物医药科技有限公司 一种巴洛沙韦酯中间体的合成方法
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
IL325937A (en) * 2023-07-24 2026-03-01 Univ Miami AAV-delivered antibodies and methods of using them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051010A1 (en) * 2013-10-02 2015-04-09 Medimmune, Llc Neutralizing anti-influenza a antibodies and uses thereof
WO2017123685A1 (en) * 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
EP2638072A4 (en) 2010-11-12 2014-05-07 Univ Rockefeller FUSION PROTEINS FOR HIV THERAPY
JP6396313B2 (ja) 2012-12-07 2018-09-26 ファイザー・インク 操作された単量体抗体断片

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051010A1 (en) * 2013-10-02 2015-04-09 Medimmune, Llc Neutralizing anti-influenza a antibodies and uses thereof
WO2017123685A1 (en) * 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
CN108697789A (zh) * 2016-01-13 2018-10-23 免疫医疗有限责任公司 治疗甲型流感的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATSUHIKO MAEDA 等: "Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody"", 《MABS》, vol. 9, no. 5, 4 May 2017 (2017-05-04), pages 844 - 853, XP055827394, DOI: 10.1080/19420862.2017.1314873 *
JONATHAN ZALEVSKY, 等: ""Enhanced antibody half-life improves in vivo activity"", NAT BIOTECHNOL, vol. 28, no. 2, pages 157, XP055308991, DOI: 10.1038/nbt.1601 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115052630A (zh) * 2019-08-29 2022-09-13 维尔生物科技有限公司 用于治疗甲型流感感染的组合物和方法
CN115777944A (zh) * 2023-02-10 2023-03-14 北京衡美金叶营养健康科技有限公司 增强身体防御力的组合物及其制备方法和应用

Also Published As

Publication number Publication date
EP3962530A1 (en) 2022-03-09
WO2020221450A1 (en) 2020-11-05
PH12021552176A1 (en) 2022-09-12
CO2021012583A2 (es) 2021-10-20
CA3132536A1 (en) 2020-11-05
CL2021002807A1 (es) 2022-08-19
JP7719725B2 (ja) 2025-08-06
AU2020265407A1 (en) 2021-10-07
EA202192923A1 (ru) 2022-02-16
US20220226470A1 (en) 2022-07-21
AU2020265407B2 (en) 2026-01-08
TW202106707A (zh) 2021-02-16
KR20220003000A (ko) 2022-01-07
SG11202109683TA (en) 2021-11-29
BR112021018409A2 (pt) 2021-11-23
MX2021012984A (es) 2021-12-10
CN119192357A (zh) 2024-12-27
IL287423A (en) 2021-12-01
WO2020221908A1 (en) 2020-11-05
JP2022531556A (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
AU2020265407B2 (en) Antibodies and methods for treatment of influenza A infection
CN102164613B (zh) 中和抗甲型流感病毒抗体及其用途
EP2846832B1 (en) Novel ha binding agents
JP6595448B2 (ja) 治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法
JP2022521819A (ja) インフルエンザを処置および予防するための組成物および方法
CN115551885A (zh) 用于治疗和预防流感的组合物和方法
US20230340083A1 (en) Antibodies and methods for treatment of influenza a infection
HK40067817A (en) Antibodies and methods for treatment of influenza a infection
US20220306728A1 (en) Compositions and methods for treatment of influenza a infection
EA048000B1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
EA050175B1 (ru) Композиции и способы лечения инфекции, вызываемой вирусом гриппа а
HK40074693A (en) Compositions and methods for treatment of influenza a infection
HK40035221A (en) Novel ha binding agents
HK1208619B (en) Novel ha binding agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067817

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220401